( NYSE:LCI )

News from Lannett Company, Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Nov 09, 2017, 06:56 ET Lannett To Present At The Jefferies 2017 London Healthcare Conference On November 15

Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the Jefferies London Healthcare Conference on November 15, 2017...


Nov 06, 2017, 16:15 ET Lannett Reports Solid Fiscal 2018 First-Quarter Financial Results, Significantly Increases Fiscal 2018 Guidance

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2018 first quarter ended September 30, 2017. "In recent weeks,...


Nov 01, 2017, 06:53 ET Lannett Comments On Amended Civil Complaint

Lannett Company, Inc. (NYSE: LCI) today responded to the allegations in the amended civil complaint by a number of states' attorneys general...


Oct 30, 2017, 06:52 ET Lannett And Celgene Enter Into Settlement And License Agreement Related To Thalomid®

Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into a settlement and license agreement with Celgene Corporation that...


Oct 26, 2017, 06:51 ET Lannett To Report Fiscal 2018 First-Quarter Financial Results, Host Conference Call On Monday, November 6

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2018 first quarter on Monday, November 6,...


Oct 02, 2017, 06:56 ET Lannett Receives Two FDA Approvals For Lansoprazole Delayed-Release Capsules USP, One Each For Full Prescription And OTC

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New...


Sep 27, 2017, 06:51 ET Lannett Receives FDA Approval For Oxycodone And Acetaminophen Tablets USP, 5 mg/325 mg And 10 mg/325 mg

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New...


Sep 26, 2017, 06:53 ET Lannett Receives Approval For Dexmethylphenidate Hydrochloride Tablets, 2.5 mg, 5 mg And 10 mg

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New...


Sep 26, 2017, 06:40 ET Lannett Announces Dismissal Of Class Action Lawsuit

Lannett Company, Inc. (NYSE: LCI) today announced that the United States District Judge for the Eastern District of Pennsylvania dismissed in its...


Sep 25, 2017, 06:54 ET Lannett's Board Of Directors Initiates CEO Search

Lannett Company, Inc. (NYSE: LCI) today announced that its board of directors has begun a search for a new chief executive officer (CEO). As part...


Sep 22, 2017, 06:53 ET Arthur Bedrosian, Lannett CEO, Prevails In Lawsuit With Internal Revenue Service

Arthur Bedrosian, chief executive officer of Lannett Company, Inc. (NYSE: LCI), has prevailed in his lawsuit with the U.S. Internal Revenue Service...


Sep 05, 2017, 06:53 ET Lannett Receives Approval For Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg And 40 mg

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New...


Aug 23, 2017, 16:24 ET Lannett Reports Fiscal 2017 Fourth-Quarter And Full-Year Financial Results, Provides Guidance For Fiscal 2018

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2017 fourth quarter and full year ended June 30, 2017. "In the...


Aug 08, 2017, 06:54 ET Lannett Announces Preliminary Fiscal 2017 Fourth-Quarter And Full-Year Financial Results, Comments On Fiscal 2018 Outlook

Lannett Company, Inc. (NYSE: LCI) today reported preliminary financial results for its fiscal 2017 fourth quarter and full year ended June 30,...


Jul 17, 2017, 06:53 ET Lannett Appoints Samuel H. Israel As General Counsel

Lannett Company, Inc. (NYSE: LCI) today announced the appointment of Samuel H. Israel as vice president, chief legal officer and general...


Jul 14, 2017, 06:53 ET Lannett Receives Approval For Cyproheptadine Hydrochloride Syrup, 2 mg/5 mL

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New...


Jun 26, 2017, 06:51 ET Lannett Receives Approval For Additional Dosage Strengths Of Hydrocodone Bitartrate And Acetaminophen Tablets USP

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New...


Jun 22, 2017, 06:53 ET Lannett Receives Approval For Hydrocodone Bitartrate and Acetaminophen Tablets USP, 5 mg/300 mg, 7.5 mg/300 mg And 10 mg/300 mg

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New...


Jun 20, 2017, 06:52 ET Lannett Names Patrick G. LePore To Board of Directors

Lannett Company, Inc. (NYSE: LCI) today announced that Patrick G. LePore has been appointed to the company's Board of Directors, effective July 1,...


Jun 19, 2017, 06:53 ET Lannett Receives Approval For Niacin Extended-Release Tablets USP, 500 Mg And 1000 Mg

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New...


Jun 16, 2017, 06:53 ET Lannett Announces Approval For Amantadine Hydrochloride Capsules USP, 100 mg

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New...


May 26, 2017, 06:53 ET Lannett Company's Chief Executive Officer Receives High Rating

Lannett Company, Inc. (NYSE: LCI) today announced that its chief executive officer, Arthur Bedrosian, received a top rating in a report by Owler,...


May 16, 2017, 06:52 ET Lannett Announces Approval For Levocetirizine Dihydrochloride Oral Solution, 2.5 mg/5 mL (0.5 mg/mL)

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New...


May 09, 2017, 06:53 ET Lannett Voluntarily Pays Down Remaining $25 Million Principal Balance Of Revolving Credit Facility

Lannett Company, Inc. (NYSE: LCI) today announced that the company voluntarily paid down the remaining principal balance of $25 million against its...


May 02, 2017, 16:15 ET Lannett Reports Fiscal 2017 Third-Quarter Financial Results

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2017 third quarter ended March 31, 2017. "Net sales in our...